Stem Cell Therapy Process: Murphy the Irish Wolfhound
Murphy is a 6 year old Irish Wolfhound who is both a service dog and a therapy dog. When he tore his ACL and then fell and fractured his pelvis, we had only ...
By: wesbroAZ
See the rest here:
Stem Cell Therapy Process: Murphy the Irish Wolfhound - Video
Stem Cell therapy in India for ischemic heart disease (ISD)
ISD can be treated with stem cell therapy at StemRx Bioscience Solutions. In case of above patient we have seen drastic improvement is heart functioning.
By: StemRx BioScience
Read the original here:
Stem Cell therapy in India for ischemic heart disease (ISD) - Video
Stem Cell Treatment for Pets | Roger A. Mauer DVM on Channel 8 News | Las Vegas
http://veterinary-stemcell.com Dr. Mauer is very excited to be offering Stem Cell Therapy. This innovative and affordable treatment has been making news all ...
By: Roger Mauer
Continued here:
Stem Cell Treatment for Pets | Roger A. Mauer DVM on Channel 8 News | Las Vegas - Video
Seoul St. Mary`s Hospital performs 5,000th hematopoietic stem cell transplantation OCTOBER 11, 2013 05:40 Seoul St. Mary`s Hospital performs 5,000th hematopoietic stem cell transplantation . OCTOBER 11, 2013 05:40. . The Seoul St. Mary`s Hospital on Thursday became Asia`s first medical institution to perform 5,000 transplants of hematopoietic stem cells. Hematopoietic stem cell transplantation is a treatment involving the infusion of blood-forming stem cells into patients of blood tumors such as leukemia, malignant lymphoma and multiple myeloma.
The Seoul St. Mary`s Hospital has reached the milestone 30 years after it performed Korea`s first successful transplantation of hematopoietic stem cells between two brothers in 1983. In the number of such hematopoietic stem cell transplantations, the hospital ranks sixth in the world and first in Asia. In transplantations of allergenic hematopoietic stem cell transplantation, the hospital ranks the fourth in the world. It is also the country`s first hospital to successfully perform autologous hematopoietic stem cell transplantation, umbilical cord blood transplantation and nonmyeloablative stem cell transplantation.
The hospital`s 5,000th patient who underwent the hematopoietic stem cell transplant is an 18-year-old leukemic girl, who received bone marrows from her younger brother.
"An analysis shows that we are one of the best performers in the world, as the rate is 10 to 30 percent higher than in the United States, as the survival rate of our 5,000 transplantation surgeries is 20 to 30 percent higher than U.S. hospitals," said Dr. Lee Jong-wook, head of the hospital`s hematopoietic stem cell transplantation center. "There is no need to go overseas for leukemia treatments."
The Seoul St. Mary`s Hospital has reached the milestone 30 years after it performed Korea`s first successful transplantation of hematopoietic stem cells between two brothers in 1983. In the number of such hematopoietic stem cell transplantations, the hospital ranks sixth in the world and first in Asia. In transplantations of allergenic hematopoietic stem cell transplantation, the hospital ranks the fourth in the world. It is also the country`s first hospital to successfully perform autologous hematopoietic stem cell transplantation, umbilical cord blood transplantation and nonmyeloablative stem cell transplantation.
The hospital`s 5,000th patient who underwent the hematopoietic stem cell transplant is an 18-year-old leukemic girl, who received bone marrows from her younger brother.
"An analysis shows that we are one of the best performers in the world, as the rate is 10 to 30 percent higher than in the United States, as the survival rate of our 5,000 transplantation surgeries is 20 to 30 percent higher than U.S. hospitals," said Dr. Lee Jong-wook, head of the hospital`s hematopoietic stem cell transplantation center. "There is no need to go overseas for leukemia treatments."
Go here to read the rest:
donga.com[English donga]
Jim Keays and Russell Morris Source: Supplied
AUSTRALIAN rock legend Jim Keays has narrowly survived acute renal failure after a radical stem cell transplant he hopes will save his life.
Keays was diagnosed with multiple myeloma - a cancer of the blood's plasma cells - six years ago and has been battling the disease since.
Myeloma often attacks the kidneys and Keays had chemotherapy and was put on dialysis after seeing his kidney function drop to 5 per cent.
Early this year he had a transplant using stem cells harvested from his own blood.
But in radical, and still experimental, surgery, he recently received stem cells from an unknown donor - a man who does not even share Keays' blood group.
"There is a global register of stem cells donors, and the doctors told me they had found a reasonable match on it," the former Master's Apprentices' frontman explained.
All Keays, who turned 67 last month, knows of the donor is that he is 28 and from New Jersey.
When doctors explained the treatment Keays was told it was his "last roll of the dice".
"The alternative was to die," said Keays.
View post:
Rocker's stem cell transplant hope
MELBOURNE, Australia and NEW YORK, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (MBLTY) today announced the acquisition of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (OSIR) by the Mesoblast Group.
"The many commercial and strategic benefits of this transaction firm Mesoblast's leadership position in the global regenerative medicine industry," said Mesoblast Chief Executive Officer Professor Silviu Itescu.
The benefits derived from acquiring the approved and late-phase MSC products include:
"Importantly, in 2014 we plan to have active products in Phase 3 clinical trials in all four core major therapeutic areas of focus: cardiovascular medicine (congestive heart failure), inflammatory/immune diseases (Crohn's disease), orthopedics (spinal fusion and intervertebral disc repair) and oncology (acute Graft versus Host Disease, and cord blood expansion in bone marrow transplantation)."
Existing cash reserves are sufficient to meet current and new product development plans. Cost savings and other synergies are expected across personnel, capital expenditure, and manufacturing, and as a result there will only be a modest increase in operating cash burn.
Strategic and Financial Benefits of the Transaction
Significant new and early potential revenue stream with the acquisition of Prochymal(R), the world's first approved stem cell therapeutic and the only stem cell therapeutic designated by the United States Food and Drug Administration (FDA) as both an Orphan Drug and Fast Track product. Prochymal(R) has already received conditional approval in Canada and New Zealand for the treatment of children with acute GvHD, and is available in the United States under an Expanded Access Program for treatment of acute GvHD in both children and adults.
A broadening of Mesoblast's Phase 3-ready products in two new indications:
Crohn's disease - a major driver for the transaction was Mesoblast's evaluation of the ongoing, 330-patient, Phase 3 trial in patients with Crohn's disease who have failed other biologic agents. Following an interim analysis for futility after 207 patients were enrolled, the best performing Prochymal dose (based on the primary endpoint of disease remission) was selected to complete the study.
Acute GvHD - the promising Phase 3 data in adults with GvHD at high risk of death due to liver or gut complications was another major driver for the transaction, and Mesoblast intends to seek approval from the FDA for this indication.
Excerpt from:
MESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL THERAPEUTIC BUSINESS
Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected.
Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well.
The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years.
These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants.
Advertisement
In afternoon trading, the shares were up 5.1 per cent at $5.76.
Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells which can help body tissue heal large wounds, repair cartilage and muscle tissue.
Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan.
The US companys product is already approved for use in selected bone marrow cases involving children in the US, Canada and New Zealand.
The purchase gives Mesoblast access to two products in phase 3 trials - a treatment for Crohns disease and for selected bone marrow cases involving adults as well, it said.
Here is the original post:
Mesoblast jumps on stem cell asset purchase
Mesoblast Ltd. (MSB) climbed the most in eight months in Sydney trading after agreeing to buy a stem-cell business of Osiris Therapeutics Inc. (OSIR) for as much as $100 million to gain new treatments.
The maker of stem-cell therapies rose as much as 11 percent, the largest advance since Feb. 7, and was up 6.2 percent to A$5.82 as of 11:47 a.m. in Sydney trading.
Mesoblast will buy the mesenchymal stem-cell unit of Osiris, including Prochymal, a treatment for acute graft versus host disease, Columbia, Maryland-based Osiris said in a statement. The price tag includes as much as $50 million in payments if certain trial and regulatory milestones are met, and Osiris may also receive royalties on sales of certain products, Melbourne-based Mesoblast said in a separate statement today.
Prochymal has received conditional approval in Canada and New Zealand for use in children with acute graft versus host disease, and is available under an access program in the U.S. for treating both children and adults, according to Osiriss statement. The illness is a complication that can occur after a stem-cell or bone-marrow transplant in which the newly transplanted donor cells attack the transplant recipients body, according to Medline Plus.
To contact the reporter on this story: Lena Lee in Singapore at llee42@bloomberg.net
To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net
See the rest here:
Mesoblast Rises on Plan to Buy Stem-Cell Business: Sydney Mover
Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected.
Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well.
The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years.
These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants.
Advertisement
In afternoon trading, the shares were up 5.1 per cent at $5.76.
Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells which can help body tissue heal large wounds, repair cartilage and muscle tissue.
Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan.
The US companys product is already approved for use in selected bone marrow cases involving children in the US, Canada and New Zealand.
The purchase gives Mesoblast access to two products in phase 3 trials - a treatment for Crohns disease and for selected bone marrow cases involving adults as well, it said.
Silviu Itescu.
Shares in stem cell group Mesoblast surged to two-month highs on its decision on Friday to outlay up to $US100 million to buy a suite of patents in the US that hold the potential to deliver revenues sooner than expected.
In a deal with US-based Osiris Therapeutic for an initial $US20 million in cash, along with further future payments, Mesoblast is to gain access to two products in their final stage of clinical trials which already hold approvals for sale in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years.
''These are substantially derisked,'' Mesoblast chief executive Silviu Itescu said of the two advanced products, an agent for treating some Crohn's disease cases along with a treatment for bone marrow cases resulting from stem cell transplants.
Mesoblast shares closed up 4.7 per cent on Friday at $5.74.
Advertisement
Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells that can help body tissue heal large wounds and repair cartilage and muscle tissue.
Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan.
The acquisition consolidates Mesoblast's position in the regenerative therapies sector, while providing additional growth options, Professor Itescu said.
The acquisition includes approved products in several countries and will ''more than double our portfolio of granted patent families encompassing all mesenchymal lineage stem cells'', he said. The products will bring forward Mesoblast's projected revenues and provide earlier launch opportunities for products, he said.
Here is the original post:
Mesoblast's US patents deal lifts shares